Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Depreciation and Depletion (2021)

Actinium Pharmaceuticals (ATNM) has disclosed Depreciation and Depletion for 2 consecutive years, with $104571.0 as the latest value for Q4 2021.

  • On a quarterly basis, Depreciation and Depletion changed N/A to $104571.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $105000.0, a N/A change, with the full-year FY2024 number at $197000.0, down 4.83% from a year prior.
  • Depreciation and Depletion was $104571.0 for Q4 2021 at Actinium Pharmaceuticals, up from $112.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $104571.0 in Q4 2021 to a low of $104571.0 in Q4 2021.